Apogee Therapeutics Inc SEC Filings

Apogee Therapeutics, Inc. is offering 6,951,221 shares of voting common stock and, in lieu of shares to certain investors, 365,853 pre-funded warrants at a public offering price of $41.00 per share (pre-funded warrants priced at $40.99999). The company estimates net proceeds of approximately $281.0M, or about $323.3M if the underwriters fully exercise a 30-day option to purchase an additional 1,097,561 shares. Proceeds are intended to fund preclinical and clinical development, manufacturing, commercial readiness and general corporate purposes, and together with existing cash are expected to fund operations into the first half of 2028. Recent clinical updates include an increased Part B enrollment target of 320 patients for the APEX Phase 2 APG777 atopic dermatitis trial, with Part A topline maintenance data expected in Q1 2026 and Part B 16-week induction topline data expected in Q2 2026, and Phase 1b asthma topline data expected in Q1 2026. The pre-funded warrants will not be listed and have limited liquidity; holders have no stockholder rights until exercise.

Apogee Therapeutics, Inc. is offering shares of its voting common stock and, in lieu of shares for certain investors, pre-funded warrants exercisable at $0.00001 per share. The company’s common stock trades on Nasdaq under the symbol APGE and had a last reported sale price of $39.73 on October 7, 2025. Apogee is a clinical-stage biotech focused on antibody programs for inflammatory and immunology indications, including atopic dermatitis and asthma.

Recent updates increase the planned Part B enrollment in the APEX Phase 2 trial of APG777 to 320 patients, with Part A maintenance topline data expected in Q1 2026, Part B 16-week induction topline in Q2 2026, and Phase 1b asthma topline in Q1 2026. The prospectus discloses pro forma historical net tangible book value of $619.4M ($10.39 per share as of June 30, 2025) and warns of dilution, limited liquidity for pre-funded warrants, and the need for additional capital to reach regulatory approval and commercialization.

Apogee Therapeutics (APGE) filed a Form 4 for its Chief Medical Officer. On 10/01/2025, the officer exercised 2,385 stock options at $22.86 and sold 5,110 shares at a weighted average price of $39.8 pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

Following these transactions, beneficial ownership stood at 284,733 shares held directly. Derivative holdings included 161,625 stock options remaining. The option referenced represents the right to purchase 175,345 shares, vesting in forty-eight equal monthly installments through December 18, 2027.

Apogee Therapeutics Chief Medical Officer Carl Dambkowski reported sales of common stock under a Rule 10b5-1 trading plan adopted August 21, 2024. On 09/03/2025 he sold 2,535 shares at a weighted-average price of $37.82 (individual trade prices ranged $37.39–$38.37) and sold 190 shares at a weighted-average price of $38.55 (trade range $38.54–$38.55). Following those reported transactions the filing shows beneficial ownership totals of 233,738 and 233,548 shares on the separate reporting lines. The Form 4 was signed by an attorney-in-fact on 09/05/2025.

Apogee Therapeutics (APGE) is a clinical-stage biotech focused on inflammatory and immunology targets. The company reported a six-month net loss of $121.4 million and an accumulated deficit of $427.4 million. Research and development expense rose sharply to $102.1 million for the six months ended June 30, 2025 (compared with $61.9 million a year earlier), while general and administrative was $34.2 million.

The balance sheet shows $124.2 million of cash and cash equivalents, $381.2 million of current marketable securities and $115.8 million of long-term marketable securities, totaling roughly $621.2 million of liquidity. Operating cash used was $110.5 million in the first six months of 2025, and management states these resources should fund operations for at least the next 12 months. The company continues to advance multiple programs (IL-13, IL-4Rα, OX40L, TSLP) under licenses from Paragon and maintains manufacturing and supply agreements with WuXi Biologics and Samsung Biologics, with related milestone and service payments disclosed.

Apogee Therapeutics, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this Current Report as Exhibit 99.1, and a Cover Page Interactive Data File is provided as Exhibit 104.

The filing states that the exhibit furnished under Item 2.02 is not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. The registrant is Apogee Therapeutics, Inc., incorporated in Delaware, trading on the Nasdaq Global Market under the symbol APGE.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics (APGE), reported a sale of 2,725 shares of Apogee common stock on 08/06/2025 at a reported price of $37.78 per share. The transaction is recorded on a Form 4 and was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024, a plan described in the filing as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

The filing shows that following the reported sale Mr. Dambkowski beneficially owned 236,273 shares, held directly. No derivative transactions are reported on this Form 4 and the document is limited to the single non-derivative sale and the related ownership position.